본문 바로가기
KERD
논문KCI 등재

Prophylactic and Therapeutic Modulation of Innate and Adaptive Immunity Against Mucosal Infection of Herpes Simplex Virus

Ajit Mahadev Patil|Erdenebileg Uyangaa|어승국
대한면역학회 (The Korean Association of Immunologists)|2014.08|Immune Network|제14권 제4호|pp. 187-200

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Adaptive immunityHerpes simplex virusToll-like receptorsInnate immunityMucosal infectionType I IFN receptors

초록

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are the most common cause of genital ulceration in humans worldwide. Typically, HSV-1 and 2 infections via mucosal route result in a lifelong latent infection after peripheral replication in mucosal tissues, thereby providing potential transmission to neighbor hosts in response to reactivation. To break the transmission cycle, immunoprophylactics and therapeutic strategies must be focused on prevention of infection or reduction of infectivity at mucosal sites. Currently, our understanding of the immune responses against mucosal infection of HSV remains intricate and involves a balance between innate signaling pathways and the adaptive immune responses. Numerous studies have demonstrated that HSV mucosal infection induces type I interferons (IFN) via recognition of Toll-like receptors (TLRs) and activates multiple immune cell populations, including NK cells, conventional dendritic cells (DCs), and plasmacytoid DCs. This innate immune response is required not only for the early control of viral replication at mucosal sites, but also for establishing adaptive immune responses against HSV antigens. Although the contribution of humoral immune response is controversial, CD4＋ Th1 T cells producing IFN-γ are believed to play an important role in eradicating virus from the hosts. In addition, the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral burden at mucosal sites have accumulated. This review focuses on attempts to modulate innate and adaptive immunity against HSV mucosal infection for the development of prophylactic and therapeutic strategies. Notably, cells involved in innate immune regulations appear to shape adaptive immune responses. Thus, we summarized the current evidence of various immune mediators in response to mucosal HSV infection, focusing on the importance of innate immune responses.

Abstract

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are the most common cause of genital ulceration in humans worldwide. Typically, HSV-1 and 2 infections via mucosal route result in a lifelong latent infection after peripheral replication in mucosal tissues, thereby providing potential transmission to neighbor hosts in response to reactivation. To break the transmission cycle, immunoprophylactics and therapeutic strategies must be focused on prevention of infection or reduction of infectivity at mucosal sites. Currently, our understanding of the immune responses against mucosal infection of HSV remains intricate and involves a balance between innate signaling pathways and the adaptive immune responses. Numerous studies have demonstrated that HSV mucosal infection induces type I interferons (IFN) via recognition of Toll-like receptors (TLRs) and activates multiple immune cell populations, including NK cells, conventional dendritic cells (DCs), and plasmacytoid DCs. This innate immune response is required not only for the early control of viral replication at mucosal sites, but also for establishing adaptive immune responses against HSV antigens. Although the contribution of humoral immune response is controversial, CD4＋ Th1 T cells producing IFN-γ are believed to play an important role in eradicating virus from the hosts. In addition, the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral burden at mucosal sites have accumulated. This review focuses on attempts to modulate innate and adaptive immunity against HSV mucosal infection for the development of prophylactic and therapeutic strategies. Notably, cells involved in innate immune regulations appear to shape adaptive immune responses. Thus, we summarized the current evidence of various immune mediators in response to mucosal HSV infection, focusing on the importance of innate immune responses.

참고문헌 (138)

  1. Mansur, D. S., "Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1", Am. J. Pathol, 166, pp.1419~1426 (2005)
  2. Roizman. B., "Fields Virology", pp.2399~2459 (2001), Lippincott Williams & Wilkins
  3. Ellermann-Eriksen, S., "Macrophages and cytokines in the early defence against herpes simplex virus", Virol. J, 2, pp.59~ (2005)
  4. Chan, T., "Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa", J. Reprod. Immunol, 88, pp.210~218 (2011)
  5. Wakimoto, H., "Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells", Gene Ther, 10, pp.983~990 (2003)
  6. Kim, M, "Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes", J. Immunol, 188, pp.4158~4170 (2012)
  7. Harandi, A. M, "Differential roles of B cells and IFN-gamma-secreting CD4(＋) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice", J. Gen. Virol, 82, pp.845~853 (2001)
  8. Verschoor, "Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection", J. Immunol, 167, pp.2446~2451 (2001)
  9. Da, C., "Humoral response to herpes simplex virus is complement-dependent", Proc. Natl. Acad. Sci. U. S. A, 96, pp.12708~12712 (1999)
  10. Kwant-Mitchell, A, "Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model", J. Virol, 83, pp.10664~10676 (2009)
  11. Gebhardt, B. M, "Effect of combinations of antiviral drugs on herpes simplex encephalitis", Drug Des Devel. Ther, 3, pp.289~294 (2009)
  12. Bourne, K. Z, "Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2", Antiviral Res, 42, pp.219~226 (1999)
  13. Bernstein, D. I., "Herpes simplex virus vaccines", Vaccine, 17, pp.1681~1689 (1999)
  14. Kawai, T., "Pathogen recognition with Toll-like receptors", Curr. Opin. Immunol, 17, pp.338~344 (2005)
  15. Takeda, K, "Toll-like receptors", Annu. Rev. Immunol, 21, pp.335~376 (2003)
  16. Kawai, T., "TLR signaling", Cell Death Differ, 13, pp.816~825 (2007)
  17. Doyle, S. L, "Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity", Biochem. Pharmacol, 72, pp.1102~1113 (2006)
  18. Menasria, R, "Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection", J. Virol, 87, pp.7301~7308 (2013)
  19. Wang, J. P., "Role of specific innate immune responses in herpes simplex virus infection of the central nervous system", J. Virol, 86, pp.2273~2281 (2012)
  20. Aravalli, R. N., "Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus", J. Immunol, 175, pp.4189~4193 (2005)
  21. Schachtele, S. J, "Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2", J. Neuroinflammation, 7, pp.35~ (2010)
  22. Krieg, A. M, "CpG motifs in bacterial DNA trigger direct B-cell activation", Nature, 374, pp.546~459 (1995)
  23. Hochrein, H., "Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways", Proc. Natl. Acad. Sci. U. S. A, 101, pp.11416~11421 (2004)
  24. Sorensen, L. N., "TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain", J. Immunol, 181, pp.8604~8612 (2008)
  25. Krug, A, "Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9", Blood, 103, pp.1433~1437 (2004)
  26. Tengvall, S, "Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice", J. Reprod. Immunol, 78, pp.49~57 (2008)
  27. Guo, Y, "Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity", J. Exp. Med, 208, pp.2083~2098 (2011)
  28. Reinert, L. S., "TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice", J. Clin. Invest, 122, pp.1368~1376 (2012)
  29. Swann, J. B, "Type I IFN contributes to NK cell homeostasis, activation, and antitumor function", J. Immunol, 178, pp.7540~7549 (2007)
  30. Isaacs, A., "Virus interference. II. Some properties of interferon", Proc. R. Soc. Lond B Biol. Sci, 147, pp.268~273 (1957)
  31. Liu, Y. J, "IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors", Annu. Rev. Immunol, 23, pp.275~306 (2005)
  32. Janeway, C. A, "Immunobiology. The immune system in health and disease", pp.461~516 (2005), Garland Science
  33. Kotenko, S. V., "IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex", Nat. Immunol, 4, pp.69~77 (2003)
  34. Sheppard, P, "IL-28, IL-29 and their class II cytokine receptor IL-28R", Nat. Immunol, 4, pp.63~68 (2003)
  35. Gill, N., "Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production", J. Virol, 80, pp.9943~9950 (2006)
  36. Rasmussen, S. B., "Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems", J. Virol, 81, pp.13315~13324 (2007)
  37. Conrady, C. D, "Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection", J. Virol, 85, pp.1625~1633 (2011)
  38. Conrady, C. D., "A functional type I interferon pathway drives resistance to cornea herpes simplex virus type 1 infection by recruitment of leukocytes", J. Biomed. Res, 25, pp.111~119 (2011)
  39. Conrady, C. D, "IFN-alpha-driven CCL2 production recruits inflammatory monocytes to infection site in mice", Mucosal. Immunol, 6, pp.45~55 (2013)
  40. Gill, N, "NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection", Cell Immunol, 269, pp.29~37 (2011)
  41. Milligan, G. N, "Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract", Virology, 229, pp.259~268 (1997)
  42. Mikloska, Z., "Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission", J. Virol, 75, pp.11821~11826 (2001)
  43. Dobbs, M. E., "Clearance of herpes simplex virus type 2 by CD8＋ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms", J. Virol, 79, pp.14546~14554 (2005)
  44. Cantin, E., "Role for gamma interferon in control of herpes simplex virus type 1 reactivation", J. Virol, 73, pp.3418~3423 (1999)
  45. Doyle, S. E., "Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes", Hepatology, 44, pp.896~906 (2006)
  46. Zhou, Z., "Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases", J. Virol, 81, pp.7749~7758 (2007)
  47. Marcello, T, "Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics", Gastroenterology, 131, pp.1887~1898 (2006)
  48. Ank, N, "Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo", J. Virol, 80, pp.4501~4509 (2006)
  49. Ank, N., "An important role for type III interferon (IFN-lambda", IL-28) in TLR-induced antiviral activity, 2008, pp.180, 2474~2485
  50. Iversen, M. B, "Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs", J. Virol, 84, pp.4579~4586 (2010)
  51. Li, J., "Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons", Glia, 59, pp.58~67 (2011)
  52. Li, J, "Induction of interferon-gamma contributes to Toll-like receptor 3-mediated herpes simplex virus type 1 inhibition in astrocytes", J. Neurosci. Res, 90, pp.399~406 (2012)
  53. Ghiasi, H, "The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection", Antiviral Res, 45, pp.33~45 (2000)
  54. Lehmann, C, "Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells", Br. J. Haematol, 114, pp.660~665 (2001)
  55. Ashkar, A. A, "Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection", J. Virol, 77, pp.10168~10171 (2003)
  56. Reading, P. C., "IL-18, but not IL-12, regulates NK cell activity following intranasal herpes simplex virus type 1 infection", J. Immunol, 179, pp.3214~3221 (2007)
  57. Nandakumar, S, "Natural killer cells as novel helpers in anti-herpes simplex virus immune response", J. Virol, 82, pp.10820~10831 (2008)
  58. Staats, H. F., "Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1＋ cells", J. Virol, 65, pp.6008~6014 (1991)
  59. Kassim, S. H., "In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses", J. Virol, 80, pp.3985~3993 (2006)
  60. Zhao, X, "Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2", J. Exp. Med, 197, pp.153~162 (2003)
  61. Sato, A., "Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments", Proc. Natl. Acad. Sci. U. S. A, 101, pp.16274~16279 (2004)
  62. Reske, A., "Glycoprotein-dependent and TLR2-independent innate immune recognition of herpes simplex virus-1 by dendritic cells", J. Immunol, 180, pp.7525~7536 (2008)
  63. Kassim, S. H., "Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1", J. Virol, 83, pp.3175~3186 (2009)
  64. Frank, G. M, "Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea", J. Immunol, 188, pp.1350~1359 (2012)
  65. Bryant-Hudson, K. M., "PD-L1-expressing dendritic cells contribute to viral resistance during acute HSV-1 infection", Clin. Dev. Immunol, 2012, pp.924619~ (2012)
  66. Lund, J., "Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells", J. Exp. Med, 198, pp.513~520 (2003)
  67. Shen, H, "A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN- based vaginal microbicide", J. Clin. Invest, 116, pp.2237~2243 (2006)
  68. Lund, J. M, "Cutting Edge: Plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ", J. Immunol, 177, pp.7510~7514 (2006)
  69. Mott, "A role for the JAK-STAT1 pathway in blocking replication of HSV-1 in dendritic cells and macrophages", Virol. J, 6, pp.56~ (2009)
  70. Swaminathan, S, "Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties", Biochem. Biophys. Res. Commun, 434, pp.228~234 (2013)
  71. Mott, K. R., "Macrophage IL-12p70 signaling prevents HSV-1-induced CNS autoimmunity triggered by autoaggressive CD4＋ Tregs", Invest Ophthalmol. Vis. Sci, 52, pp.2321~2333 (2011)
  72. Zolini, G. P, "Defense against HSV-1 in a murine model is mediated by iNOS and orchestrated by the activation of TLR2 and TLR9 in trigeminal ganglia", J. Neuroinflammation, 11, pp.20~ (2014)
  73. Iijima, N., "Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue", Proc. Natl. Acad. Sci. U. S. A, 108, pp.284~289 (2011)
  74. Milligan, G. N, "Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2", J. Virol, 73, pp.6380~6386 (1999)
  75. Molesworth-Kenyon, S. J., "Resident corneal cells communicate with neutrophils leading to the production of IP-10 during the primary inflammatory response to HSV-1 infection", Int. J. Inflam, 2012, pp.810359~ (2012)
  76. Wojtasiak, M., "Depletion of Gr-1＋, but not Ly6G＋, immune cells exacerbates virus replication and disease in an intranasal model of herpes simplex virus type 1 infection", J. Gen. Virol, 91, pp.2158~2166 (2010)
  77. Parr, M. B., "Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice", Immunology, 101, pp.126~131 (2000)
  78. Gorander, S, "Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease", J. Virol, 86, pp.7544~7553 (2012)
  79. Liu, K., "Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy", Vaccine, 30, pp.3034~3041 (2012)
  80. Deshpande, S. P., "Pathogenesis of herpes simplex virus-induced ocular immunoinflammatory lesions in B-cell-deficient mice", J. Virol, 74, pp.3517~3524 (2000)
  81. Peek, R, "Herpes simplex virus infection of the human eye induces a compartmentalized virus-specific B cell response", J. Infect. Dis, 186, pp.1539~1546 (2002)
  82. Iijima, N., "Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus", J. Exp. Med, 205, pp.3041~3052 (2008)
  83. Del, C. J, "Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice", Vaccine, 28, pp.1193~1200 (2010)
  84. Cortesi, R., "Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes", Int. J. Pharm, 440, pp.229~237 (2013)
  85. Chiuppesi, F, "A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections", J. Virol, 86, pp.6563~6574 (2012)
  86. Kuklin, N. A., "Role of mucosal immunity in herpes simplex virus infection", J. Immunol, 160, pp.5998~6003 (1998)
  87. Dudley, K. L, "Immune protection against HSV-2 in B-cell-deficient mice", Virology, 270, pp.454~463 (2000)
  88. Morrison, L. A., "Vaccine- induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells", J. Virol, 75, pp.1195~1204 (2001)
  89. Bettelli, E, "Induction and effector functions of T(H)17 cells", Nature, 453, pp.1051~1057 (2008)
  90. Suryawanshi, A, "Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology", J. Immunol, 187, pp.1919~1930 (2011)
  91. Eo, S. K., "Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines", J. Virol, 75, pp.569~578 (2001)
  92. Kumamoto, Y, "CD4＋ T cells support cytotoxic T lymphocyte priming by controlling lymph node input", Proc. Natl. Acad. Sci. U. S. A, 108, pp.8749~8754 (2011)
  93. The role of CD4＋ Helper T cells, IL-2 and IL-15 in the generation of an optimal CD8＋ T cell response following infection with herpes simplex virus-1 (HSV-1), "Rajasagi, N. K", Louisiana State University Health Sciences Center, 56~61, pp.Shreveport, ProQuest, UMI Dissertations Publishing Number: 3311956 (2007)
  94. Ghiasi, H, "Wechsler. 2000. Both CD4＋ and CD8＋ T cells are involved in protection against HSV-1 induced corneal scarring", Br. J. Ophthalmol, 84, pp.408~412 (2000)
  95. Koelle, D. M., "Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes", J. Clin. Invest, 101, pp.1500~1508 (1998)
  96. Coleman, C. A., "T regulatory cells: aid or hindrance in the clearance of disease?", J. Cell Mol. Med, 11, pp.1291~1325 (2007)
  97. Dasgupta, G., "Engagement of TLR2 reverses the suppressor function of conjunctiva CD4＋CD25＋ regulatory T cells and promotes herpes simplex virus epitope-specific CD4＋CD25− effector T cell responses", Invest Ophthalmol. Vis. Sci, 52, pp.3321~3333 (2011)
  98. Sehrawat, S., "In vitro-generated antigen-specific CD4＋ CD25＋ Foxp3＋ regulatory T cells control the severity of herpes simplex virus-induced ocular immunoinflammatory lesions", J. Virol, 82, pp.6838~6851 (2008)
  99. Kim, J. O., "Pathological effect of IL-17A-producing TCRgammadelta(＋) T cells in mouse genital mucosa against HSV-2 infection", Immunol. Lett, 147, pp.34~40 (2012)
  100. Jirmo, A. C., "Contribution of direct and cross-presentation to CTL immunity against herpes simplex virus 1", J. Immunol, 182, pp.283~292 (2009)
  101. St Leger, A. J., "Defining the herpes simplex virus-specific CD8＋ T cell repertoire in C57BL", 6 mice, 2011, pp.186, 3927~3933
  102. van, L. A., "Herpes simplex virus-specific CD8＋ T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation", J. Immunol, 172, pp.392~397 (2004)
  103. Koelle, D. M., "Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes", J. Clin. Invest, 101, pp.1500~1508 (1998)
  104. Himmelein, S., "Circulating herpes simplex type 1 (HSV-1)-specific CD8＋ T cells do not access HSV-1 latently infected trigeminal ganglia", Herpesviridae, 2, pp.5~ (2011)
  105. Koelle, D. M, "Herpes simplex: insights on pathogenesis and possible vaccines", Annu. Rev. Med, 59, pp.381~395 (2008)
  106. Wilson, S. S, "Novel approaches in fighting herpes simplex virus infections", Expert. Rev. Anti. Infect. Ther, 7, pp.559~568 (2009)
  107. Petrera, E., "Effect of the potent antiviral 1-cinnamoyl-3,11-dihydroxymeliacarpin on cytokine production by murine macrophages stimulated with HSV-2", Phytother. Res, pp.104~109 (2014)
  108. Akira, S, "Pathogen recognition and innate immunity", Cell, 124, pp.783~801 (2006)
  109. Miller, R. L, "Immunomodulation as a treatment strategy for genital herpes: review of the evidence", Int. Immunopharmacol, 2, pp.443~451 (2002)
  110. Ashkar, A. A, "Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA", J. Infect. Dis, 190, pp.1841~1849 (2004)
  111. Boivin, N, "Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis", J. Infect. Dis, 198, pp.664672~ (2008)
  112. Ashkar, A. A, "Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2", J. Virol, 77, pp.8948~8956 (2003)
  113. Gill, N, "The role of toll-like receptor ligands", agonists in protection against genital HSV-2 infection, 2008, pp.59, 35~43
  114. Sajic, D, "Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina", Immunology, 114, pp.213~224 (2005)
  115. Tumpey, T. M., "Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10", J. Leukoc. Biol, 63, pp.486~492 (1998)
  116. Kratholm, S. K, "Interleukin-21 receptor signalling is important for innate immune protection against HSV-2 infections", PLoS One, 8, pp.e81790~ (2013)
  117. Seong Bum Kim, "Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with β2-adrenergic agonist", Experimental and Molecular Medicine, 41(11), pp.812~823 (2009), 생화학분자생물학회
  118. Lindqvist, M., "The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection", J. Immunol, 182, pp.6435~6443 (2009)
  119. Erdenebileg Uyangaa, "Glutamine and Leucine Provide Enhanced Protective Immunity Against Mucosal Infection with Herpes Simplex Virus Type 1", Immune Network, 12(5), pp.196~206 (2012), 대한면역학회[DOI]
  120. Kuo, Y. C., "Efficacy of orally administered Lobelia chinensis extracts on herpes simplex virus type 1 infection in BALB", c mice, 2008, pp.80, 206~212
  121. 조아라, "Protective effects of red ginseng extract against vaginal herpes simplex virus infection", Journal of Ginseng Research, 37(2), pp.210~218 (2013), 고려인삼학회
  122. Petrera, E, "Effect of the potent antiviral 1-cinnamoyl-3,11-dihydroxymeliacarpin on cytokine production by murine macrophages stimulated with HSV-2", Phytother. Res, 28, pp.104~109 (2014)
  123. Ushio, C., "Suppressive effects of a cyanine dye against herpes simplex virus (HSV)-1 infection", Biomed. Res, 30, pp.365~368 (2009)
  124. Balzarini, J., "A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity", PLoS Pathog, 9, pp.1003456~ (2013)
  125. Hu, K, "Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis", Immunol. Invest, 40, pp.265~278 (2011)
  126. Awasthi, S, "Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs", J. Virol, 88, pp.2000~2010 (2014)
  127. Brans, R., "Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs", BMC. Microbiol, 10, pp.163~ (2010)
  128. Koelle, D. M., "Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects", Clin. Vaccine Immunol, 15, pp.773~782 (2008)
  129. Zhang, X., "A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8＋ T cells and protects against herpes simplex virus type 2 challenge", Mucosal. Immunol, 2, pp.129143~ (2009)
  130. Jamali, A., "DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge", Comp Immunol. Microbiol. Infect. Dis, 30, pp.71~80 (2007)
  131. Johnston, C., "HSV-2: in pursuit of a vaccine", J. Clin. Invest, 121, pp.4600~4609 (2011)
  132. Belshe, R. B., "Efficacy results of a trial of a herpes simplex vaccine", N. Engl. J. Med, 366, pp.3443~ (2012)
  133. Stanberry, L. R., "Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes", J. Infect. Dis, 155, pp.914~920 (1987)
  134. Bourne, N., "Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs", J. Infect. Dis, 187, pp.542~549 (2003)
  135. Bourne, N, "Impact of immunization with glycoprotein D2", AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected, 2005, pp.192, 2117~2123
  136. Stanberry, L. R, "Glycoprotein-D-adjuvant vaccine to prevent genital herpes", N. Engl. J. Med, 347, pp.1652~1661 (2002)
  137. Corey, L., "Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group", JAMA, 282, pp.331~340 (1999)
  138. Ghasemi, M., "Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells", Cytotherapy, 15, pp.352~361 (2013)

관련 논문AI추천

단순 포진 바이러스 백신의 개발 및 도전정홍대한요로생식기감염학회 · Urogenital Tract Infection2014 · 제9권 제2호Glutamine and Leucine Provide Enhanced Protective Immunity Against Mucosal Infection with Herpes Simplex Virus Type 1어성국, 이헌구, Erdenebileg Uyangaa대한면역학회 · Immune Network2012 · 제12권 제5호Anti-herpes Activity of Vinegar-processed Daphne genkwa Flos Via Enhancement of Natural Killer Cell Activity류형원, 어성국, 오세량, 최진영, Erdenebileg Uyangaa대한면역학회 · Immune Network2015 · 제15권 제2호Roles of Type I and III Interferons in COVID-19신의철, 최호준연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제5호The Role of Plasmacytoid Dendritic Cells in Gut Health김형택, 류다혜, 원혜연, 이주영, 장선영대한면역학회 · Immune Network2019 · 제19권 제1호The Multifaceted Roles of NK Cells in the Context of Murine Cytomegalovirus and Lymphocytic Choriomeningitis Virus InfectionsThamer A. Hamdan대한면역학회 · Immune Network2024 · 제24권 제4호

이 간행물의 다른 논문 (5건)

The Roles of Innate Lymphoid Cells in the Development of Asthma정동진, 김혜영, 우연덕, 정두현pp. 171-181Interplay between Inflammatory Responses and Lymphatic Vessels신기혁, 이승효pp. 182-186IL-33 Priming Enhances Peritoneal Macrophage Activity in Response to Candida albicansHong R. Cho, 권병석, Vuvi G. Tranpp. 201-206Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection강창율, 황유경, 이아라, 하상준, 김민기pp. 207-218Relationship between Poor Immunogenicity of HLA-A2-Restricted Peptide Epitopes and Paucity of Naïve CD8＋ T-Cell Precursors in HLA-A2-Transgenic Mice최윤석, 이동호, 신의철pp. 219-225
원문 보기